Literature DB >> 15541834

Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.

M Bartnik1, K Malmberg, A Norhammar, A Tenerz, J Ohrvik, L Rydén.   

Abstract

AIMS: Recent data revealed that patients with myocardial infarction (MI) have a high prevalence of previously unknown diabetes mellitus (DM) and impaired glucose tolerance (IGT). The added prognostic importance of this finding has not been prospectively explored. To investigate whether a newly detected abnormal glucose tolerance (IGT or DM) assessed early after an MI, is related to long-term prognosis. METHODS AND
RESULTS: Patients (n=168; age 63.5+/-9.3 years) with MI, no previous DM and admission blood glucose <11.0 mmol/l were followed for major cardiovascular events defined as the composite of cardiovascular death, non-fatal MI, non-fatal stroke or severe heart failure (HF). According to an oral glucose tolerance test (OGTT) before hospital discharge, 55 patients had normal and 113 abnormal glucose tolerance (GT). During the follow-up of median 34 months there were eight cardiovascular deaths, 15 patients had a recurrent MI, six had a stroke and ten severe HF. All patients who died from cardiovascular causes had abnormal GT. The composite cardiovascular event occurred in 31 (18%) patients. The probability of remaining free from cardiovascular events was significantly higher in patients with normal than abnormal GT (p=0.002). Together with previous MI, abnormal GT was the strongest predictor of future cardiovascular events (hazard ratio 4.18; CI 1.26-13.84; p=0.019).
CONCLUSIONS: Abnormal glucose tolerance is a strong risk factor for future cardiovascular events after myocardial infarction. Since it is common and possible to detect even during the hospital phase it may be a target for novel secondary preventive efforts.

Entities:  

Mesh:

Year:  2004        PMID: 15541834     DOI: 10.1016/j.ehj.2004.09.021

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  51 in total

1.  Risk of type 2 diabetes mellitus in patients with acute critical illness: a population-based cohort study.

Authors:  Chin-Wang Hsu; Chin-Sheng Lin; Sy-Jou Chen; Shih-Hua Lin; Cheng-Li Lin; Chia-Hung Kao
Journal:  Intensive Care Med       Date:  2015-09-14       Impact factor: 17.440

Review 2.  Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.

Authors:  David H Fitchett; Bjug Borgundvaag; Warren Cantor; Eric Cohen; Sanjay Dhingra; Stephen Fremes; Milan Gupta; Michael Heffernan; Heather Kertland; Mansoor Husain; Anatoly Langer; Eric Letovsky; Shaun G Goodman
Journal:  Can J Cardiol       Date:  2006-06       Impact factor: 5.223

Review 3.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

4.  [Prevalence of undetected diabetes mellitus in invasive and interventional cardiology. Silent diabetes in the catheterization laboratory].

Authors:  R Dörr; J Stumpf; S G Spitzer; B Krosse; D Tschöpe; T Lohmann; O Schnell
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

Review 5.  Hyperglycemia in nondiabetic patients presenting with acute myocardial infarction.

Authors:  Binita Shah; Nicholas S Amoroso; Steven P Sedlis
Journal:  Am J Med Sci       Date:  2012-04       Impact factor: 2.378

6.  Global myocardial perfusion and diastolic function are impaired to a similar extent in patients with type 2 diabetes mellitus and in patients with coronary artery disease--evaluation by contrast echocardiography and pulsed tissue Doppler.

Authors:  V Dounis; T Siegmund; A Hansen; J Jensen; P-M Schumm-Draeger; H von Bibra
Journal:  Diabetologia       Date:  2006-09-21       Impact factor: 10.122

Review 7.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26

8.  Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Authors:  Louise Profit; Paul Chrisp; Carole Nadin
Journal:  Core Evid       Date:  2008-06

9.  Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Abdelnoor Michael; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir Ø Andersen
Journal:  Cardiovasc Diabetol       Date:  2010-09-02       Impact factor: 9.951

10.  Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Michael Abdelnoor; Jan Eritsland; Arild Mangschau; Harald Arnesen; Geir O Andersen
Journal:  Cardiovasc Diabetol       Date:  2009-01-30       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.